NDAORALTABLET
Approved
Mar 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAQUIVAL is a fixed-dose combination oral tablet containing reserpine (an antihypertensive alkaloid) and trichlormethiazide (a thiazide diuretic), approved in 1960 for hypertension management. This combination targets blood pressure reduction through dual mechanisms: reserpine acts as a sympathetic inhibitor while trichlormethiazide promotes sodium and fluid excretion. The product represents a legacy antihypertensive approach largely superseded by modern agents.
LOE Approaching
Minimal commercial investment expected; small residual patient base limits team size and growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NAQUIVAL offers limited career growth due to the product's LOE-approaching lifecycle, generic competition, and minimal market presence. Roles would focus on lifecycle management, compliance, and brand continuity rather than market expansion or innovation.
Product Manager (Specialty)Regulatory Affairs Specialist
Worked on NAQUIVAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.